Canntab Teaming Up With FSB Pharma And UBC For Cannabis Clinical Trial

Toronto-based Canntab Therapeutics Limited (CSE: PILL) is currently seeking approval from the University of British Columbia (UBC) for a clinical trial on the effects of marijuana in potentially reducing opioid use after surgery.

Canntab just announced the company has signed a term sheet with Dr. Don Garbuz to handle the proposed double-blind clinical trial, pending University approval.

Dr. Garbuz, an orthopedic surgeon, currently serves as a faculty member in the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at UBC.

This news comes just slightly over a week after Canopy Growth Corporation (TSX: WEED) also teamed up with the University of British Columbia to establish the new Professor of Cannabis Science position.

That position is also focused on utilizing cannabis as a means of battling the North American opioid epidemic.

Dr. Don Garbuz had this to say about signing the term sheet and his upcoming duties running the

... read more at: